Form 4: Zai Lab's Chief Legal Officer Receives Stock Options and Restricted Share Units

Frazor Titus Edmondson III, Chief Legal Officer of Zai Lab, reports the acquisition of stock options and restricted share units (RSUs) on March 12, 2025.

Summary

• On March 12, 2025, Frazor Titus Edmondson III, the Chief Legal Officer of Zai Lab, was granted stock options and restricted share units.
• The stock options grant consists of 52,418 options with an exercise price of $35.55.
• These options vest in equal annual installments over four years, starting on March 12, 2026, contingent upon continuous service.
• Additionally, 17,035 restricted share units (RSUs) were granted, each representing a contingent right to receive one American Depositary Share (ADS).
• The RSUs also vest in equal annual installments over four years, beginning on March 12, 2026, subject to continuous service, with vested shares delivered as ADSs.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral to slightly positive signal.

Positives

• The grant of stock options and RSUs aligns the Chief Legal Officer's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment and continuous service from the executive.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the options and RSUs.

Industry Context

Granting stock options and RSUs to key executives is a common practice in the biotech industry to incentivize performance and retain talent. This aligns with standard compensation practices.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice in the pharmaceutical industry, particularly for companies like Zai Lab that are focused on research and development.
• Comparable companies such as BeiGene and Hutchmed also utilize equity-based compensation to attract and retain key personnel.
• The vesting schedules (four-year annual vesting) are typical for these types of grants.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
• Employees may see this as a positive sign of investment in key personnel.

Key Dates